
CAR-T HIV Therapy Lets Patients Ditch Daily Drugs for Months
A tiny CAR-T trial kept two HIV patients off daily drugs for up to 20 months, hinting at durable immune control—not a cure.
May 25, 20261 min read0 reactions0 comments
Tag archive

A tiny CAR-T trial kept two HIV patients off daily drugs for up to 20 months, hinting at durable immune control—not a cure.

CAR-T cell therapy costs $500K per dose with a 30-day manufacturing bottleneck. Flow cytometry QC — still largely manual — is the rate-limiting step. As next-day manufacturing emerges, AI-automated an